About Us

Veterinary parasitic diseases are a continuous threat to animal health and the cause of immense economic losses all over the world. Fasciolosis, the most important parasitic infection for livestock, alone has an impact of multiple billions of dollars to the food industry. Heartworm affects dogs and cats by the millions, carrying a treatment cost of up to 200 dollars for each animal every year.

The solutions based on vaccines such as the Sm14 recombinant protein allow a fundamental shift in this scenario. Our pipeline lists safe and effective vaccines for the immunoprophylaxis of major veterinary parasitic infections, with efficient and environmentally-friendly technology.

The company is a startup whose business model is structured around business partnerships to take products to regulatory approval in regional- and country-level markets. Licensing deals with companies familiar with relevant market dynamics and regulatory frameworks allow our products to reach consumers, promoting animal health with financial sustainability.

Background

FABP Biotech emerged from decades of work on anti-parasitic vaccines. The heart of our technology, the Sm14 recombinant protein, has been the object of scientific study and technological development through a global network of partnerships led by a team of scientists working at Brazil’s Fiocruz. This network has successfully brought the Sm14 protein through the main obstacles and bottlenecks in biotechnological development, achieving stability, safety, and immunogenicity in different vaccine formulations. At the core of this success is the coordination of synergistic aspects of scientific inquiry, technological development, and economic insight regarding the two-fold development of human and animal vaccines. This dynamic is still at play, as the development of veterinary vaccines in FABP Biotech’s portfolio works in tandem with the advances in the human vaccine currently undergoing Phase II Clinical Trials.

Background

FABP Biotech

Technology

Contact